31/03/2021
2021-03-31
false
false
false
false
false
false
false
false
false
false
true
false
false
true
false
false
false
false
false
false
false
false
No description of principal activities is disclosed
2020-04-01
Sage Accounts Production 2020 Update 1 - FRS102_2014
xbrli:pure
xbrli:shares
iso4217:GBP
08794088
2020-04-01
2021-03-31
08794088
2021-03-31
08794088
2019-04-01
2020-03-31
08794088
2020-03-31
08794088
bus:RegisteredOffice
2020-04-01
2021-03-31
08794088
bus:LeadAgentIfApplicable
2020-04-01
2021-03-31
08794088
bus:Director1
2020-04-01
2021-03-31
08794088
bus:Director6
2020-04-01
2021-03-31
08794088
bus:Director7
2020-04-01
2021-03-31
08794088
bus:Director8
2020-04-01
2021-03-31
08794088
bus:Director9
2020-04-01
2021-03-31
08794088
bus:Director10
2020-04-01
2021-03-31
08794088
core:WithinOneYear
2021-03-31
08794088
core:WithinOneYear
2020-03-31
08794088
core:ShareCapital
2021-03-31
08794088
core:ShareCapital
2020-03-31
08794088
core:RetainedEarningsAccumulatedLosses
2021-03-31
08794088
core:RetainedEarningsAccumulatedLosses
2020-03-31
08794088
bus:SmallEntities
2020-04-01
2021-03-31
08794088
bus:AuditExemptWithAccountantsReport
2020-04-01
2021-03-31
08794088
bus:FullAccounts
2020-04-01
2021-03-31
08794088
bus:SmallCompaniesRegimeForAccounts
2020-04-01
2021-03-31
08794088
bus:PrivateLimitedCompanyLtd
2020-04-01
2021-03-31
Company registration number:
08794088
Procare Health Limited
Unaudited filleted financial statements
31 March 2021
Procare Health Limited
Directors and other information
|
|
|
|
|
Directors |
Dr A Cook |
|
|
|
Dr P A Ridsdill Smith |
|
|
|
Dr R S Barai |
|
|
|
Mr R Curtin |
(Appointed on 01.05.2020) |
|
|
Ms W Newnham |
(Appointed on 01.05.2020) |
|
|
Ms C G Rawlings |
(Appointed on 01.05.2020) |
|
|
|
|
|
|
|
|
|
Company number |
08794088 |
|
|
|
|
|
|
|
|
|
|
Registered office |
The Brentano Suite |
|
|
|
Solar House |
|
|
|
915 High Road |
|
|
|
North Finchley |
|
|
|
N12 8QJ |
|
|
|
|
|
|
|
|
|
|
Accountants |
Ramsay Brown LLP |
|
|
|
The Brentano Suite |
|
|
|
Solar House |
|
|
|
915 High Road |
|
|
|
North Finchley |
|
|
|
N12 8QJ |
|
|
|
|
|
Procare Health Limited
Statement of financial position
31 March 2021
|
|
|
2021 |
|
|
|
2020 |
|
|
|
|
Note |
£ |
|
£ |
|
£ |
|
£ |
|
|
|
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
|
|
Debtors |
|
5 |
845,841 |
|
|
|
379,345 |
|
|
|
Investments |
|
6 |
1 |
|
|
|
- |
|
|
|
Cash at bank and in hand |
|
|
1,598,594 |
|
|
|
1,313,243 |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
|
|
|
|
2,444,436 |
|
|
|
1,692,588 |
|
|
|
Creditors: amounts falling due |
|
|
|
|
|
|
|
|
|
|
within one year |
|
7 |
(
2,355,297) |
|
|
|
(
1,615,857) |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
|
|
Net current assets |
|
|
|
|
89,139 |
|
|
|
76,731 |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
Total assets less current liabilities |
|
|
|
|
89,139 |
|
|
|
76,731 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
_______ |
|
|
|
_______ |
|
Net assets |
|
|
|
|
89,139 |
|
|
|
76,731 |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
|
|
|
|
|
|
|
|
|
|
Capital and reserves |
|
|
|
|
|
|
|
|
|
|
Called up share capital |
|
|
|
|
19 |
|
|
|
19 |
|
Profit and loss account |
|
|
|
|
89,120 |
|
|
|
76,712 |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
Shareholders funds |
|
|
|
|
89,139 |
|
|
|
76,731 |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
|
|
|
|
|
|
|
|
|
For the year ending 31 March 2021 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors responsibilities:
-
The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
-
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.
These financial statements were approved by the
board of directors
and authorised for issue on
28 September 2021
, and are signed on behalf of the board by:
Dr P A Ridsdill Smith
Director
Company registration number:
08794088
Procare Health Limited
Notes to the financial statements
Year ended 31 March 2021
1.
General information
The company is a private company limited by shares, registered in England & Wales. The address of the registered office is The Brentano Suite, Solar House, 915 High Road, North Finchley, N12 8QJ.
2.
Statement of compliance
These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
3.
Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Turnover
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer, usually on despatch of the goods; the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Operating leases
Lease payments are recognised as an expense over the lease term on a straight-line basis. The aggregate benefit of lease incentives is recognised as a reduction to expense over the lease term, on a straight-line basis.
Research and development
Research expenditure is written off in the year in which it is incurred. Development expenditure incurred is capitalised as an intangible asset only when all of the following criteria are met: - It is technically feasible to complete the intangible asset so that it will be available for use or sale; - There is the intention to complete the intangible asset and use or sell it; - There is the ability to use or sell the intangible asset; - The use or sale of the intangible asset will generate probable future economic benefits; - There are adequate technical, financial and other resources available to complete the development and to use or sell the intangible asset; and - The expenditure attributable to the intangible asset during its development can be measured reliably. Expenditure that does not meet the above criteria is expensed as incurred.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets or either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
Share-based payments
Equity-settled share-based payment transactions are measured at fair value at the date of grant. The fair value is expensed on a straight-line basis over the vesting period, with a corresponding increase in equity. This is based upon the company's estimate of the shares or share options that will eventually vest which takes into account all vesting conditions and non-market performance conditions, with adjustments being made where new information indicates the number of shares or share options expected to vest differs from previous estimates. Fair value is determined using an appropriate pricing model. All market conditions and non-vesting conditions are taken into account when estimating the fair value of the shares or share options. As long as all other vesting conditions are satsfied, no adjustment is made irrespective of whether market or non-vesting conditions are met. Where the terms of an equity-settled transaction are modified, an expense is recognised as if the terms had not been modified. In addition, an expense is recognised for any increase in the fair value of the transaction, as measured at the date of modification. Where an equity-settled transaction is cancelled or settled, it is treated as if it had vested on the date of cancellation or settlement, and any expense not yet recognised in profit or loss is expensed immediately. Cash-settled share-based payment transactions are measured at the fair value of the liability. Until the liability is settled, the fair value of the liability is re-measured at each reporting date and at the date of settlement, with any changes in fair value recognised in profit or loss for the period.
4.
Employee numbers
The average number of persons employed by the company during the year amounted to
16
(2020:
16
).
5.
Debtors
|
|
|
2021 |
2020 |
|
|
|
£ |
£ |
|
Trade debtors |
|
115,389 |
283,008 |
|
Other debtors |
|
730,452 |
96,337 |
|
|
|
_______ |
_______ |
|
|
|
845,841 |
379,345 |
|
|
|
_______ |
_______ |
|
|
|
|
|
6.
Investments
|
|
|
2021 |
2020 |
|
|
|
£ |
£ |
|
Investments in PCS |
|
1 |
- |
|
|
|
_______ |
_______ |
|
|
|
|
|
7.
Creditors: amounts falling due within one year
|
|
|
2021 |
2020 |
|
|
|
£ |
£ |
|
Trade creditors |
184,195 |
63,553 |
|
|
|
Amount Due to PCN |
|
1,105,709 |
761,256 |
|
Corporation tax |
|
2,911 |
1,162 |
|
Social security and other taxes |
|
47,339 |
6,876 |
|
Other creditors |
|
1,015,143 |
783,010 |
|
|
|
_______ |
_______ |
|
|
|
2,355,297 |
1,615,857 |
|
|
|
_______ |
_______ |
|
|
|
|
|
